Journal of Phytomolecules & Pharmacology

Research Article

An in silico ADME/T and molecular docking studies of C-glycosyl flavones derived from *Peperomia blanda* (Jacq.) Kunth for the management of diabetes

Florensa Rosani Purba¹* ⓘ, Ika Rahayu² ⓘ and Kris Herawan Timotius² ⓘ

1. Faculty of Engineering and Computer Sciences, Krida Wacana Christian University (UKRIDA), Jakarta, Indonesia.
2. Faculty of Medicine and Health Sciences, Krida Wacana Christian University (UKRIDA), Jakarta, Indonesia.

Abstract

The present *in silico* study was to compile the results of interaction between C-glucosyl flavone ligands from *Peperomia blanda* (vitexin, isovitexin, schaftoside, vicenin 2 and vicenin 3) and multi-diabetic proteins (α-amylase, α-glucosidase, GLUT1, DPP4, PTP1B). The sdf 3D formats of five bioactive C-glycosylated flavones were obtained from the PubChem database. The proteins were obtained from the Protein Data Bank. Protein preparation was performed using BIOVIA Discovery Studio 2021 Client 21.1. All ligands and proteins were converted to pdbqt format using Pyrx 0.8. Subsequently, docking was conducted using Pyrx 0.8. Molsoft, Molinspiration, and Swiss ADME were used to evaluate the ligand's properties and drug-likeness score. Five ligands of C-glycosylated flavones from *Peperomia blanda*, like vitexin, isovitexin, schaftoside, vicenin 2, and vicenin 3 are potent inhibitors of α-amylase, α-glucosidase, GLUT1, DPP4, PTP1B, their capacity is comparable with quercetin and other controls. *Peperomia blanda* is a potential herb for antidiabetic therapy due to its C-glucosylated flavone content. Moreover, C-glucosylated flavones can be considered significant compounds for antidiabetic therapy.

1. Introduction

The number of people with T2DM is increasing globally. The use of synthetic antidiabetic drugs has side effects accompanying the current epidemiological burden of T2DM. Alternatively, numerous herbal materials can decrease blood sugar levels by inhibiting diabetes-related multi-proteins. However, the putative antidiabetic properties of herbal materials remain scattered [1-2].

Peperomia is the second largest species of the Piperaceae family. Nevertheless, only a few species of *Peperomia* have been investigated for their bioactive compounds. *Peperomia blanda* (Fig. 1) is a native shrub to tropical sites like Asia, Africa, Australasia, and Polynesia. Its habitat is on damp rocks, crevices, and

Figure 1. *Peperomia blanda*

J. Phytomol. Pharmacol. 2(2), 83-94, 2023

Florensa Rosani Purba et al., 2023

steep stream banks, creeping and crawling around river ledges and tree trunks. As an arid-land shrub, it is drought and wind-tolerant. It grows as a perennial, succulent herb to 30-60 cm in height [3] *Peperomia* species have been recorded to have numerous uses as traditional medicine to treat skin diseases, burns, eye infections, asthma and antibiotics [4]. In addition, *Peperomia blanda* has various uses in traditional remedies. It has been reported to be used for treating cancer, inflammation, and infection [5]. As far as our knowledge, no report is available for its antidiabetic potential. But reports on its bioactive compounds, particularly C-glycosylated flavone of *Peperomia blanda* indicate its antidiabetic potential [6].

Five C-glycosyl flavones (shown in Fig. 2), vitexin, isovitexin, schaftoside, vicenin 2, and vicenin 3, have been detected from polar or aqueous extracts of *Peperomia blanda* leaves.


Figure 2. Chemical structure of vitexin, isovitexin, schaftoside, vicenin-2, and vicenin 3 (PubChem) [56]

They possess significant bioactivities, including antimicrobial activity (isoorientin, vitexin), hepatoprotective activity (isoorientin), and antioxidant activity (isovitexin). In addition, they may become new and more efficacious antidiabetic herbal drugs and nutraceuticals to lessen the global burden

of diabetes [2, 7]. Bioactive compounds such as C-glycosyl flavones may potentially inhibit the activity of multi-diabetic proteins. These proteins may become targets of C-glycosyl flavone. This study selects five diabetic-associated proteins: α-amylase, α-glucosidase, GLUT1, DPP4, and PTP1B.

T2DM is associated with multiple genes (polygenic), but modern pharmacological interventions mainly apply a monogenic approach, "single drug for single target." Applying this principle requires a high drug dose that increases the probability of adverse events. Therefore, as an alternative principle, an antidiabetic formula generally found in traditional pharmacological interventions can target multiple diabetic proteins and possesses antidiabetic activity at a low dose with minimal side effects. Polygenic diseases, like T2DM, can be targeted via multiple pathways by herbal formula. Lead bioactive compounds in antidiabetic herbal formulas can modulate multiple proteins involved in T2DM. Segregating phytoconstituents from the herbal material can target multiple proteins for better therapeutic outcomes [8].

The present study aimed to compile *in silico* studies between several ligands of C-glucosyl flavone from *Peperomia blanda* with multiple proteins associated with T2DM. Thus, this study aimed to predict an in-silico molecular docking approach to screen and support the antidiabetic property of *Peperomia blanda*. Their binding affinities of C-glucosyl flavone ligands with target proteins associated with T2DM were evaluated, as well as the hydrogen bond residues and drug-likeness scores.

1.1 Short overview of multi-diabetic-related proteins

1.1.1 α-amylase and α-glucosidase

α-Amylase and α-glucosidase are responsible for the breakdown of polysaccharides into glucose for further absorption. Their inhibition can help to control blood glucose levels. In this case, acarbose is often used for T2DM therapy to inhibit these enzymes.

1.1.2 Glucose transporter 1 (GLUT1)

Glucose enters or leaves cells principally with the assistance of two membrane-integrated transporters belonging either to the facilitative glucose transporters (GLUTs) or to the sodium-glucose cotransporters (SGLTs) [9] Several glucose transporters, such as GLUT1, GLUT2, GLUT3, GLUT4,

and GLUT5, mediate the facilitative uptake of glucose into cells. GLUT1 is a Na and insulin-independent, uniport facultative transporter. It has an essential role in several cells, such as in cells in the blood, blood-brain barrier, cornea, intestinal glucose absorption and transport from epithelial cells into the bloodstream [9], in glomeruli of the kidney [10-11], in heart muscle cells and muscle tissue [12], and in the retina [13]. Human beta cells of the pancreas express mainly GLUT1. GLUT1 overexpression is associated with obesity and non-insulin-dependent diabetes, although the correlation is still unknown [14]. Therefore, GLUT1 is considered a promising therapeutic target for T2DM [13].

GLUT1 inhibitors, like metformin, forskolin, and genistein, may reduce glucose level transport [12] Forskolin or genistein can bind GLUT1, inhibit glucose transport, and significantly reduce retinal glucose. In contrast, brain glucose levels are not increased in people with diabetes or reduced by forskolin [13]. Particular natural products can function as GLUT1 inhibitors, like rubusoside and curcumin. *In silico* analysis of rubusoside pinpoint a tryptophan residue in GLUT1 [15]. Curcumin has an immediate inhibitory effect on basal glucose uptake. It binds directly to GLUT1 at a site that overlaps with the cytochalasin B binding site [16].

1.1.3 Protein tyrosine phosphatase 1 B (PTP1B)

Insulin resistance caused by the overexpression of PTP1B is one of the leading causes of T2DM. PTP1B has fundamental regulatory roles and is a critical negative and positive regulator of several signaling cascades. PTP1B's direct regulation of the insulin and the leptin receptors makes it an ideal therapeutic target for T2DM [17].

The role of PTP1B in the pathogenesis of T2DM is related to insulin resistance, which is caused mainly by impairment in the insulin receptor (IR) signal transduction pathway. PTP1B is one of the main negative regulators of the IR signaling pathway, which is broadly expressed in various cells and tissues. PTP1B decreases the phosphorylation of the IR, resulting in insulin resistance in various tissues. Recently, targeting PTP1B using PTP1B inhibitors has been considered an attractive target for treating T2DM. PTP1B inhibitors improve the sensitivity of the insulin receptor and can cure insulin resistance-related

diseases [18-19].

1.1.4 Dipeptidyl Peptidase 4 (DPP4)

The incretin system is a potential source of therapies for T2DM. Administered glucose can stimulate a substantial release of insulin. Two incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) trigger the gastrointestinal tract to release insulin whenever glucose is consumed. These incretin hormones bind to receptors on beta cells of the pancreas, thereby stimulating insulin secretion in response to glucose absorption. Nevertheless, their secretion is decreased in patients with T2DM. Increasing GLP-1 levels decreases hyperglycaemia. GIP is not active in patients with T2DM. In addition to glucose-dependent insulin secretion, GLP-1 regulates glucose homeostasis via inhibition of glucagon secretion (thereby reducing liver glucose output) and gastric emptying [20].

GLP-1 is an essential molecular target in light of T2DM. In T2DM, resolving insulin resistance and impairing insulin secretion is crucial. Incretin is a collective peptide hormone released from the digestive tract with glucose or food intake and acts on the β cells of the pancreas to stimulate insulin release. GIP and GLP-1 are two incretins known so far. Because the sensitivity of GLP-1 in the β cells of the pancreas is not reduced in T2DM patients, it is considered for the prevention and treatment of T2DM. GLP-1 enhances insulin secretion depending on the blood glucose concentration. GLP-1 is a potent endogenous therapeutic agent for the treatment of T2DM and has been proven to protect pancreatic β-cells from glucotoxicity; however, its mode of action is not clearly understood. Probably, GLP-1 may protect β-cells from glucotoxicity by promoting autophagy through the modulation of 5'AMP-activated protein kinase (AMPK) [21].

GIP and GLP1 are potential in glucose-induced insulin and suppression of glucagon secretion. However, they are rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). DPP4 destroys the incretins that are responsible for improving pancreatic beta cell function. DPP-4 inhibition is essential in treating T2DM [20, 22] Therefore, the dipeptidyl peptidase-4 inhibitors, exenatide, sitagliptin, vildagliptin, and liraglutide, are important

therapeutic agents.[20, 22-25].

1.2. C-glycosyl flavone of Peperomia blanda: vitexin, isovitexin, schaftoside, vicenin 2 and vicenin 3

The polar extracts of *Peperomia blanda* are rich in two C-glycosyl flavones, namely vitexin, and vicenin 2 (Fig. 2). They exist in the methanol extract from aerial parts of the *P. blanda*. Vitexin and vicenin 2 have numerous biological activities, like antioxidant and antidiabetic activity and antiosteoporosis [26] Moreover, vicenin 2 is a potential agent for treating bone-related disorders [27] and has a beneficial effect on neurological and cognitive function and in treating liver diseases. It can protect LPS-induced liver damage by inhibiting the TLR-mediated inflammatory pathway [28].

In vitro and *in vivo* studies have been performed with vitexin and isovitexin derivatives relating to T2DM. Vitexin and isovitexin have multitargeted mechanistic actions in controlling T2DM. Vitexin and isovitexin can target diverse pathophysiological and metabolic pathways and molecular drug points involved in the clinical manifestations of T2DM [29] Vitexin can be given as oral medicament to reduce the postprandial blood glucose level. Oral administration of vitexin can decrease the postprandial blood glucose level. Moreover, vitexin does not show toxicity. Its capacity is probably due to the ability of vitexin to inhibit *in vivo* α-glucosidase [26].

Schaftoside is found also in *Peperomia blanda*. However, it is not yet used in traditional medicine for treating T2DM. The α-glucosidase (AGI) activities were lower than the antidiabetic drug acarbose. Schaftoside is responsible for the AGI activity [30].

As vitexin, vicenin-2 is also known as an antidiabetic flavonoid. Even though the antidiabetic-related experiment using vicenin 2 from *Peperomia blanda* is not yet investigated, even vicenin 2 is found in *Peperomia blanda*. The presence of vicenin 2 indicates that *Peperomia blanda* might have antidiabetic potential. Its antidiabetic potential is due to the inhibitory activity against α-glucosidase, advanced glycation end products (AGE) formation, PTP1B, and rat lens aldose reductase (RLAR). Therefore, vicenin-2-rich extract might be valuable in treating T2DM and its associated complications [31]. In addition, topical application of vicenin 2 may improve diabetic wound healing due to its antibacterial activity [32-33].

2. Materials and methods

2.1 Method of Docking studies

Five C-glycosyl flavones were retrieved from the published literature [26-28]. Their sdf 3D format was obtained from the PubChem database along with its canonical SMILES, molecular weight, and molecular formula. All ligands were converted to pdbqt format using Pyrx 0.8.

Five different target diabetic proteins were retrieved from the RCSB Protein Data Bank, namely α-amylase (PDB ID: 1B2Y), α-glucosidase (PDB ID: 3WY1), GLUT1 (PDB ID: 5EQI), PTP1B (PDB ID2: NT7), and DPP4 (PDB ID: 4J3J). Protein preparation was performed using BIOVIA Discovery Studio 2021 Client 21.1, Water molecules and native ligands on the protein were removed, and then hydrogen was added. The prepared protein was then converted to pdbqt format using Pyrx 0.8. The precise placement of the active site during the docking process in Pyrx 0.8 was enabled by establishing the coordinates (X, Y, and Z) of the active site using Discovery Studio. The active site position was set as follows: α-amylase (x: 18.9; y: 5.7; z:47), α-glucosidase (x: -8.6; y: -15.5; z: 21.3), GLUT1 (x: -39.4; y: 11.3; z:12.1), PTP1B (x: 48.1; y: 10.1 ; z:2.9), DPP4 (x: 5.3; y: 16.3 ; z:-23). Subsequently, docking was performed using Pyrx 0.8. Ligand-protein interactions were analyzed using BIOVIA Discovery Studio 2021 Client 21.1.

2.2 Drug-likeness scoring

MolSoft and Swiss-ADME were used to evaluate the drug-likeness scoring of the five C-glycosyl flavones.

3. Results

T2DM is a polygenic metabolic disorder that involves many functional proteins. Many antidiabetic drugs are inhibitors, like α-amylase, α-glucosidase inhibitors, DPP4 inhibitors, etc. *Peperomia blanda,* as a traditional medicine plant, possesses C-glucosyl flavones that prove their antidiabetic potential by inhibiting multi-diabetic-associated proteins. The bioinformatics tools are essential in the current pharmacology for the screening the bioactive compounds from traditional plants. Molecular docking is an *in-silico* approach for finding the lead hit, which gives information about the binding affinity of the bioactive compounds to a particular receptor. Binding affinity is inversely proportional to the

Table 1. Binding affinity (kcal/mol) of ligands from *Peperomia blanda* with targets multi proteins associated with T2DM.

Proteins	Vitexin	Isovitexin	Scaftoside	Vicenin-2	Vicenin-3	Controls	Quercetin (this study)	Quercetin [8]
α-Amylase	-8.5	-8.8	-9.1	-8.8	-9.1	-7.1 (acarbose)	-9.1	-9.0
α-Glucosidase	-6.8	-8.9	-9.5	-8.7	-8.8	-8.3 (acarbose)	-8.0	-7.8
GLUT-1	-10.3	-10.1	-11.0	-10.4	-11.0	-4.7 (metformin)	-8.7	-7.2
DPP4	-8.2	-8.3	-8.5	-8.3	-8.6	-6.8 (Saxagliptin)	-7.8	-8.2
PTP1B	- 7.2	-7.8	-7.2	-7.3	-7.3	-0.7 (Sitagliptin)	-8.2	-8.7

binding energy of the phytoconstituents with targeted protein. Our study outlined the possible binding energies for five C-glucosyl flavones from *P. blanda* with five different targets (α-amylase, α-glucosidase, GLUT1, *PTP1B*, *DPP4*), which can be targeted for the management of diabetes.

Molecular docking is an *in-silico* approach for finding the lead hit, which gives information about the binding affinity of the bioactive compounds to a particular receptor. Binding affinity is inversely proportional to the binding energy of the phytoconstituents with targeted protein. Our study outlined the possible binding energies for five different C-glucosyl flavones from *Peperomia blanda* with five different targets (α-amylase, α-glucosidase, GLUT1, PTP1B, and DPP4), which can be targeted for the management of diabetes. In our study, C-glucosyl flavone from *P.blanda* was found to bind with these proteins with binding energies comparable to or more vital than controls (Table 1). All C-glucosyl flavones tested possessed the highest binding affinity towards GLUT1. All C-glucosyl flavones tested involved hydrogen and Pi-Stalked, and Pi-alkyl bond residues for binding with the five proteins: α-amylase, α–glucosidase, GLUT1, DPP4, and PTP1B, as represented in Table 2. As a representative model, a picture of the interactions between vitexin and GLUT1 is presented in Fig.3.

Oral bioavailability for the absorption of a drugable molecule affects the pharmacokinetics and pharmacodynamics properties associated with biological spectra. Hence, in the present study, we attempt to investigate the C-glucosyl flavones for their oral biostability using the "Rule of Five" model using MolSoft as explained by Lipinksi in which vitexin scored the highest drug-likeness score, i.e.,

Figure 3. Interaction of vitexin with GLUT1 (a) 3D pose of vitexin with GLUT1, (b) ligand binding site, (c) 2D plot of vitexin with GLUT1

0.60 with the molecular weight of 304,25 Da, seven hydrogen bond acceptors, five hydrogen bond donors, and 0.71 molLogP contributing to the antidiabetic effect. Similarly, isovitexin scored 0.59. Both scored slightly higher than quercetin as control (0.52). The other C-glucosyl flavones, such as schaftoside, vicenin 2, and vicenin 3 scored 0.32, 0.20, and 0.32, respectively, as depicted in Table 3.

4. Discussion

Flavones belong to the group of flavonoids, present in

J. Phytomol. Pharmacol. 2(2), 83-94, 2023

Florensa Rosani Purba et al., 2023

Table 2. The interaction between the protein catalytic site-associated T2DM and C-glycosyl flavones

Proteins	Ligands						
	Vitexin	**Isovitexin**	**Schaftoside**	**Vicenin 2**	**Vicenin 3**	**Quercetin [8]**	**controls**
α - Amylase	AspA317	GluA233 AspA197 GluA240	AspA300 AspA197 GluA233 GluA240	GluA197 AspA300 AspA197 GluA240	GluA233 GluA240 AspA300		AspA197 Asp300 GluA233
α- Glucosidase	AspA275 AsnA276 AspA274 GluA279 GluA233	GluA377 AspA401 AsnA301	AsnA301 GluA396	GluA396 GluA377 AsnA301 AspA333 AspA401	GluA231 GluA396 AspA333 AsnA301	AspB48	AspA333 GluA396 Glu377 AsnA301 AspA401 AspA379
GLUT1	TrpA412	TrpA388	TrpA388 TrpA412	TrpA388 TrpA412	TrpA388 TrpA412	TrpA388	
DPP4	HisA740 SerA630	SerA630 HisA740	HisA740 SerA630	HisA740 SerA630	SerA630 HisA740	SerA630 HisA740	SerA630
PTP1B	CysA215 SerA216 AlaA216	SerA216 AlaA217	CysA215 SerA216 AlaA217	SerA216 AlaA217	CysA215 SerA216 AlaA217	SerA216 AlaA217	

Note:

☐ Carbon hydrogen bond

■ Conventional hydrogen bond

☐ Van der Waals

☐ Pi-Alkyl

■ Unfavorable bump; unfavorable donor-dono

Table 3. Drug likeness score of C-glucosyl flavones from *Peperomia blanda*

C-glucosyl flavone	Mol. Wt.	NHBa	NHBd	Cons. LogP	TPSA	Vol	LogS		Drug likeness score
							Moles/L	**mg/L**	
Quercetin	302.04	7	5	1.19	102.61	281.71	-2.19	1,952.89	0.52
Vitexin	432.38	10	7	-0.07	181.05	246.32	-1.81	6,740.78	0.60
Isovitexin	432.38	10	7	0.05	181.05	355.20	-1.82	6,497.70	0.59
Schaftoside	564.49	14	10	-1.65	250.97	461.51	-1.43	20,771.27	0.32
Vicenin 2	594.52	15	11	-2.07	271.20	469.56	-1.50	18,691.85	0.20
Vicenin 3	564.49	14	10	-1.65	250.97	461.51	-1.43	20,771.27	0.32

the form of aglycone glycosylated with sugar moieties. Because of their higher stability and reactivity, Flavone-C-glycosides have better therapeutic properties than O-glycosylated flavones. The therapeutic potential of flavones and their C-glycosylated flavones is specifically on antidiabetic properties. The discussion focuses on the relationship between the physicochemical properties of C-glycosylated flavones and the biochemical pathway of diabetic syndrome [7].

All ligands tested in this study significantly inhibit five proteins, α-amylase, α-glucosidase, GLUT1, DPP4, and PPT1B. The inhibitory potential lies in their bonding energy and interactions with the amino acid residues.

Vitexin and isovitexin are available in diverse bioresources. They have been studied to explore their pharmacological relevance in T2DM. Data collected hint that vitexin and isovitexin work by targeting diverse pathophysiological and metabolic pathways and molecular drug points involved in the clinical manifestations of T2DM. They are expected to

Table 4. Antidiabetic plants with C-glycosyl flavones

Species	Common name	Part	C-glycosyl flavone	Ref.
Ajuga iva	Herb ivy	Aerial part	Vicenin 2	[57]
Artemisia capillaris	Wormwood-fragrant wormwood	Whole plant	Vicenin 2	[31]
Artemisia campestris	Field wormwood	Aerial part	Vicenin 2	[58]
Artemisia herba-alba	Desert or white wormwood	Aerial part	Vicenin 2	[57]
Aspalathus linearis	Rooibos	Leave	Vitexin, isovitexin	[59]
Beta vulgaris	Beet	Beetroot	Vitexin, isovitexin	[60]
Bombax ceiba	Red silk-cotton tree	Leave	Vitexin, isovitexin	[61]
Clinacanthus nutans	Dandang gendis	Leave	Vitexin, isovitexin, schaftoside	[62-63]
Costus spiralis	Spiral ginger	Leave	schaftoside	[30]
Cyclopia subternata	Valley tea		Vicenin 2	[64-65]
Ficus deltoidea	Golden Mistletoe Fig	Leave	Vitexin, isovitexin	[35]
Gmelina philippensis	Parrot's Beak	Aerial part	Vicenin 2	[34]
Gymnocarpos decandrus	Nachtfrucht	Flowering aerial part	Vitexin, isovitexin	[36]
Hylocereus polyrhizus	Dragon fruit or red pitaya	Fruit	Vicenin 2	[40]
Ocimum gratissimum	Basil	Leave	Vicenin 2	[47]
Peperomia blanda	The arid-plant *peperomia*	Leave	Vitexin, isovitexin, schaftoside, vicenin2, vicenin 3	This study
Peperomia pellucida	Pepper elder	Leave	Vitexin, isovitexin	[66]
Pereskia bleo	Rose cactus	Leave	Vitexin, isovitexin	[67]
Prosopis spp.		Aerial part	Schaftoside, vicenin 2	[68]
Saccharum officinarum	Sugarcane	Leave	Schaftoside	[41]
Sauromatum guttatum	Voodoo Lilly or Snake Plant	Tuber	Schaftoside, vicenin 2	[38]
Trigonella foenum-graecum	Fenugreek	Seed	Vitexin, isovitexin, schaftoside, vicenin 2	[69-71]
Vigna radiata	Mung bean	Seed coat	Vitexin, isovitexin	[45, 72]

provide a deeper understanding of its actions and serve as a catapult for clinical trials and application research [29].

Several antidiabetic plants are rich in C-glycosyl flavone, particularly vitexin, isovitexin, schaftoside, vicenin2, and vicenin 3 (Table 4). They have been proven for their potential to inhibit α-amylase and α-glucosidase. Several crude extracts from *Artemisia capillaris*, *Costus spiralis*, *Ficus deltoidea*, *Gmelina philippensis*, *Gymnocarpos decandrus*, *Hylocereus polyrhizus Sauromatum guttatum*, and *Vigna radiata* have inhibitory activities against α-amylase and α-glucosidase activities [30-31, 34-40].

All compounds have strong binding affinity to α-amylase compared to acarbose as control. Among all compounds, Scaftoside has the strongest binding affinity (-9.1 kcal/mol). Isovitexin has a higher binding affinity (-8.8 kcal/mol) towards α-amylase than vitexin (-8.3 kcal/mol) [35]. Scaftoside, Isovitexin and Vitexin are potent and stable against the α-amylase enzyme. The molecular dynamics findings showed that the vitexin-α-amylase complex is more stable during the simulation of 20 ns than the isovitexin-α-amylase complex. Thus, Vitexin could be developed as a therapeutic drug for treating diabetes [35]. The residues Asp197, Glu233, and Asp300 are crucial in inhibiting α-amylase. This finding followed by Kan *et al.* which multiple hydrogen bonds and electrostatic interactions exist between C-glycosyl flavone and α-amylase. C glycosyl flavone strongly binds with the

J. Phytomol. Pharmacol. 2(2), 83-94, 2023

Florensa Rosani Purba et al., 2023

catalytic triad (Asp197, Glu233, and Asp300,) of α-amylase [41]. The results of this study are in accordance with the opinion of Kawaga *et al.* who explained that the α-Amylase has two aspartic residues and one glutamic acid residue as the catalytic residues [42]. The docked view of our ligands showed varied binding residues on Glu and Asp. The number of amino acids does not follow the previous reports that stated the Glu276 and Asp214 as catalytic triad [43]. or Asn412, Glu304, Glu276, and Asp349 residues which are catalytic residues [44]. This difference is probably due to the different types of the enzyme.

All tested ligands showed predictive inhibitory activities against the α-glucosidase enzyme compared to control (acarbose). Scaftoside has the highest binding affinity (-9.5 kcal/mol) (Table 1). Asp333, Glu377, Val380, Glu396 residues are critical roles in binding α-glucosidase. All ligands exhibited good binding interactions within the active site of the enzyme. Nevertheless, our findings are not in accordance with the opinion of Halim et al. who reported that the docked view was at Glu276 and Asp214 residues [43].

All compounds have strong binding affinity with GLUT-1, with their strength significantly greater compared to metformin (Table 1). However, it appears that Scaftoside has the highest binding affinity at -11 kcal/mol. C-glycosyl flavone, like vitexin, can protect the cells against high glucose toxicity. Mungbean seed coat extract can increase glucose uptake [45] and improve insulin sensitivity [39]. Vitexin can improve glucose transporter-2 (GLUT-2), and glucose-stimulated insulin secretion [46-47] C-glycosyl flavone, like schaftoside and vicenin 2, can also inhibit advanced glycation end products (AGE) [31, 40]. Our ligands showed binding with residues Thr30, Thr137, Gln282, Gln283, and Asn411 playing critical roles in ligand binding to GLUT [48-49].

In this study, C glycosyl flavone tested showed significant DPP4 inhibitory effects. The results show that all the compunds have higher binding affinity compared to saxagliptin as control. Vicenin-3 has the highest binding score (-8.6 kcal/mol) (Table 1). The Arg125, Asp545, Asn710, Asp739, and Gly741 residues may play a crucial role in inhibiting DPP4 by schaftoside, vicenin 2, and vicenin 3. According to

Kan et al., the residues Arg125 and Tyr662 of DPP4 may play crucial roles in inhibiting the activity of DPP4 [41]. Residues that are important in the catalytic activity of DPP4 are residues Ser630, Asp708 and His740 (the catalytic triad), Tyr547 in the hydrolase domain, and substrate binding sites with saline bridging residues, such as Glu205, Glu206 and Tyr662 that are located in the β-propeller domain [50-51].

Vitexin, isovitexin, schaftoside, and vicenin 2 have been proven for their potent PTP1B inhibitory activity [31, 52], an enzyme overexpressed in T2DM [53]. The lack of clinically approved PTP1B inhibitors has continued to prompt research in plant-derived therapeutics, possibly due to their relatively lesser toxicity profiles. The five C-glycosyl flavones docked against the enzyme have an affinity with a binding score from -7.2 to -7.8 kcal/mol. These results follow the previous study by Rampadarath et al. which stated that reported a binding score of -7.3 kcal/mol for the interaction between vitexin and PTP1B (Table 1) [54]. The active site of PTP1B is Cysteine215 with a surrounding catalytic loop and an allosteric site surrounded by α3 helix, α6 helix, and α7 helix. An allosteric transition in PTP1B accompanying its catalysis, which is situated about 20Å away from the catalytic domain, including active site Cys215 and catalytic loop consisting of His214, Ser216, Ala217, Gly218, Ile219, Gly220, and Arg221 [55]. From the description above, it is evident that the ligands are bound to the catalytic site of the protein. This indicates that these ligands are capable of inhibiting the protein's function by binding to its active site.

The Lipinski rule outlines certain thresholds for molecular weight (MW), the number of hydrogen bond acceptors and donors (HBA and HBD), and the water/octanol partition coefficient (log P). It was determined that compounds not meeting two or more of these criteria are probably candidates for exclusion from further development. Adequate drug absorption and penetration within the body, as per Lipinski's rule, involve the following criteria: a maximum of 5 HBD, a molecular weight not exceeding 500 Da, a log P value no greater than 5, and a maximum of 10 HBA (Lipinski, 1997).56 The highest drug-likeness score is found for vitexin and isovitexin. The other compounds were scoreless due to their higher molecular weight than 500 KD. Lipinski's rule of five,

vitexin and isovitexin are the best drug-likeness rather than schaftoside, vicenin 2, and vicenin 3.

5. Conclusions

T2DM is a polygenic metabolic disorder that is associated with several proteins. *Peperomia blanda* is a non-toxic plant with multiple bioactivities that can target various pathogenic pathways and synergistically exert antidiabetic effects. Our study screened the antidiabetic potential of five C-glycosylated flavons towards five different diabetic proteins: α – amylase, α – glucosidase, GLUT1, DPP4, and PTP1B, using *in silico* molecular docking approach where C-glycosylated flavones, vitexin, isovitexin, schaftoside, vicenin 2, and vicenin 3 were found to possess higher affinity towards the five first protein targets. Thus, the C-glycosylated flavone-rich extract of *Peperomia blanda* has antidiabetic potential and can be used to investigate and develop novel antidiabetic preparations.

Abbreviations

DPP4: Dipeptidyl peptidase; GLUT1Glucose transporter 1; PTP1B: Protein tyrosine phosphatase 1-B; T2DM: type 2 diabetes mellitus;

Authors' contributions

Conceptualization, K.H.T.; Methodology, F.R.P. and I.R.; Software, I.R.; Validation, I.R. and K.H.T.; Formal analysis, writing original draft preparation, F.R.P. and I.R.; Writing–review and editing, K.H.T.; Visualization, F.R.P. and I.R.

Acknowledgements

Funding

Availability of data and materials

All data will be made available on request according to the journal policy.

Conflicts of interest

The authors declare no conflict of interest.

References

1. Lydia, A.K.; Suastika, P.; Martosuwignjo, R.P.; Sibarani, S.A.; Nasution, S.A. Early Recognition of Type 2 Diabetes Complications and Use of SGLT2i in Multidisciplinary Approach: Indonesian Perspective - An Expert Opinion. Acta Med. Indones. 2022. 54(4), 653-663.

2. Chinsembu, K.C. Diabetes mellitus and nature's pharmacy of putative antidiabetic plants. J. Herb. Med. 2019. 15, 100230. https://doi.org/10.1016/j.hermed.2018.09.001

3. USDA, "*Peperomia blanda*". The PLANTS Database (plants.usda.gov). Greensboro, North Carolina: National Plant Data Team., 2015.

4. Al-Madhagi, W.M.; Hashim, N.M.; Ali, N.A.A.; Othman, R. Phytochemical screening, cytotoxic and antimicrobial activities of *Limonium socotranum* and *Peperomia blanda* extracts. Trop. Biomed. 2019, 36(1), 11-21.

5. Al-Madhagi, W.M.; Mohd Hashim, M.N.; Ali, N.A.; Alhadi, A.A.; Abdul Halim, S.N.; Othman, R. Chemical profiling and biological activity of *Peperomia blanda* (Jacq.) Kunth. Peer. J. 2018, 6, e4839. https://doi.org/10.7717/peerj.4839.

6. Gutierrez, Y.V.; Yamaguchi, L.F.; de Moraes, M.M.; Jeffrey, C.S.; M.J. Kato, Natural products from Peperomia: occurrence, biogenesis and bioactivity. Phytochemistry Reviews, 2016, 15(6), 1009-1033. https://doi.org/10.1007/s11101-016-9461-5

7. Chua, L.S.; Abdullah, F.I.; Awang, M.A. Chapter 8 - Potential of natural bioactive C-glycosyl flavones for antidiabetic properties, in Studies in Natural Products Chemistry, R. Atta Ur, Editor. 2020, Elsevier. 241-261. https://doi.org/10.1016/B978-0-12-817903-1.00008-5

8. Chaudhary, R.K.; Karoli, S.S.; Dwivedi, P.S.R.; Bhandari, R. Anti-diabetic potential of *Corn silk (Stigma maydis):* An in-silico approach. J. Diabet. Metab. Disord. 2022, 21(1), 445-454. https://doi.org/10.1007/s40200-022-00992-7.

9. Blaschek, W., Natural products as lead compounds for sodium glucose cotransporter (SGLT) inhibitors. Planta Med. 2017, 83(12-13), 985-993. https://doi.org/10.1055/s-0043-106050

10. Hodgkinson, A.D.; Page, T.; Millward, B.A.; Demaine, A.G. *A* novel polymorphism in the 5' flanking region of the glucose transporter (GLUT1*)* gene is strongly associated with diabetic nephropathy in patients with Type 1 diabetes mellitus. J. Diabet. Comp. 2005, 19(2), 65-69. https://doi.org/10.1016/j.jdiacomp.2004.07.002

11. Heilig, C.W.; Brosius, F.C.; Cunningham, C. Role for GLUT1 in diabetic glomerulosclerosis. Expert. Rev. Mol. Med. 2006, 8(4), 1-18.

12. Fischer, Y.; Thomas, J.; Rösen, P.; Kammermeier, H. Action of metformin on glucose transport and glucose transporter GLUT1 and GLUT4 in heart muscle cells

from healthy and diabetic rats. Endocrinol. 1995. 136(2), 412-20. https://doi.org/10.1210/endo.136.2.7835271

13. Lu, L.; Seidel, C.P.; Iwase, T.; Stevens, R.K.; Gong, Y.Y.; Wang, X.; Hackett, S.F.; Campochiaro, P.A. Suppression of GLUT1; a new strategy to prevent diabetic complications. J. Cell Physiol. 2013, 228(2), 251-7. https://doi.org/10.1002/jcp.24133

14. George Thompson, A.M.; Iancu, C.V.; Nguyen, T.T.; Kim, D.; Choe, J.Y.; Inhibition of human GLUT1 and GLUT5 by plant carbohydrate products; insights into transport specificity. Sci. Rep. 2015, 5, 12804.

15. George T.A.M.; Iancu, C.V.; Nguyen, T.T.H.; Kim, D.; Choe, J.Y. Inhibition of human GLUT1 and GLUT5 by plant carbohydrate products; insights into transport specificity. Sci. Rep. 2015, 5(1), 12804. https://doi.org/10.1038/srep12804.

16. Gunnink, L.K.; Alabi, O.D.; Kuiper, B.D.; Gunnink, S.M.; Schuiteman, S.J.; Strohbehn, L.E.; Hamilton, K.E.; Wrobel, K.E.; Louters, L.L. Curcumin directly inhibits the transport activity of GLUT1. Biochimie. 2016, 125, 179-185. https://doi.org/10.1016/j.biochi.2016.03.014

17. Feldhammer, M.; Uetani, N.; Miranda-Saavedra, D.; Tremblay, M.L. PTP1B: a simple enzyme for a complex world. Crit. Rev. Biochem. Mol. Biol. 2013, 48(5), 430-45. https://doi.org/10.3109/10409238.2013.819830

18. Teimouri, M.; Hosseini, H.; Arab Sadeghabadi, Z.; Babaei-Khorzoughi, R.; Gorgani-Firuzjaee, S.; Meshkani, R.; The role of protein tyrosine phosphatase 1B (PTP1B) in the pathogenesis of type 2 diabetes mellitus and its complications. J. Physiol. Biochem. 2022, 78(2), 307-322. https://doi.org/10.1007/s13105-021-00860-7.

19. Yang, Z.; Wu, F.; He, Y.; Zhang, Q.; Zhang, Y.; Zhou, G.; Yang, H.; Zhou, P. A novel PTP1B inhibitor extracted from Ganoderma lucidum ameliorates insulin resistance by regulating IRS1-GLUT4 cascades in the insulin signaling pathway. Food Funct. 2018, 9(1), 397-406. https://doi.org/10.1039/c7fo01489a

20. Barnett, A.H.; Grice, J. The incretin system, in new mechanisms in glucose control. 2011, 17-19.

21. Miao, X.; Gu, Z.; Liu, Y.; Jin, M.; Lu, Y.; Gong, Y.; Li, L.; Li, C. The glucagon-like peptide-1 analogue liraglutide promotes autophagy through the modulation of 5'-AMP-activated protein kinase in INS-1 β-cells under high glucose conditions. Peptides. 2018, 100, 127-139. https://doi.org/10.1016/j.peptides.2017.07.006

22. Nauck, M.A.; Meier, J.J. Incretin-based therapies, in International Textbook of Diabetes Mellitus. 2015, p.p. 726-744.

23. Bloomgarden, Z. Dipeptidyl peptidase-4 inhibitor approaches. J. Diabet. 2017, 9(1), 5-7.

24. Mistry, G.C.; Bergman, A.J.; Zheng, W.; Hreniuk, D.; Zinny, M.A.; Gottesdiener, K.M.; Wagner, J.A.; Herman, G.A.; Ruddy, M. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br. J. Clin. Pharmacol. 2008, 66(1), 36-42. https://doi.org/10.1111/j.1365-2125.2008.03148.x

25. Zou, H.; Zhu, N.; Li, S. The emerging role of dipeptidyl-peptidase-4 as a therapeutic target in lung disease. Expert Opin. Ther. Targets. 2020, 24(2),147-153. https://doi.org/10.1080/14728222.2020.1721468

26. Choo, C.Y.; Sulong, N.Y.; Man, F.; Wong, T.W. Vitexin and isovitexin from the leaves of *Ficus deltoidea* with in-vivo α-glucosidase inhibition. J. Ethnopharmacol. 2012, 142(3), 776-781. https://doi.org/10.1016/j.jep.2012.05.062.

27. Velozo, L.S.; Ferreira, M.J.; Santos, M.I.; Moreira, D.L.; Guimarães, E.F.; Emerenciano, V.P.; Kaplan, M.A. C-glycosyl flavones from *Peperomia blanda.* Fitoterapia, 2009, 80(2), 119-22. https://doi.org/10.1016/j.fitote.2008.11.005

28. Lee, I.C.; Bae, J.S. Hepatoprotective effects of vicenin-2 and scolymoside through the modulation of inflammatory pathways. J. Nat. Med. 2020, 74(1), 90-97. https://doi.org/10.1007/s11418-019-01348-x

29. Abdulai, I.L.; Kwofie, S.K.; Gbewonyo, W.S.; Boison, D.; Puplampu, J.B.; Adinortey, M.B. Multitargeted effects of vitexin and isovitexin on diabetes mellitus and its complications. Sci. World J. 2021, 6641128. https://doi.org/10.1155/2021/6641128.

30. de Oliveira, A.P.; Coppede, J.S.; Bertoni, B.W.; Crotti, A.E.M.; França, S.C.; Pereira, A.M.S.; Taleb-Contini, S.H. *Costus spiralis* (Jacq.) Roscoe: A novel source of flavones with α-glycosidase inhibitory activity. Chem. Biodivers. 2018, 15(1), e1700421. https://doi.org/10.1002/cbdv.201700421.

31. Islam, M.N.; Ishita, I.J. Jung, H.A. Choi, J.S. Vicenin 2 isolated from artemisia capillaris exhibited potent anti-glycation properties. Food. Chem. Tox., 2014, 69, 55-62. https://doi.org/10.1016/j.fct.2014.03.042.

32. Tan, W.S.; Arulselvan, P.; Ng, S.F.; Mat Taib, C.N.; Sarian, M.N.; Fakurazi, S. Improvement of diabetic wound healing by topical application of Vicenin-2 hydrocolloid film on Sprague Dawley rats. BMC Complement. Alter. Med. 2019,19(1), 20. https://doi.org/10.1186/s12906-018-2427-y.

33. Tan, W.S., Arulselvan, P.; Ng, S.F.; Taib, C.N.M.; Sarian, M.N.; Fakurazi, S. Healing effect of vicenin-2 (VCN-2) on human dermal fibroblast (HDF) and development VCN-2 hydrocolloid film based on alginate as potential wound dressing. Biomed Res. Int. 2020, 4730858. https://doi.org/10.1155/2020/4730858.

34. Sayed, H.M.; Ahmed, A.S.; Khallaf, I.S.; Qayed, W.S.; Mohammed, A.F.; Farghaly, H.S.M.; Asem, A. Phytochemical investigation, molecular docking studies and DFT calculations on the antidiabetic and cytotoxic activities of *Gmelina philippensis* CHAM. J.

J. Phytomol. Pharmacol. 2(2), 83-94, 2023

Florensa Rosani Purba et al., 2023

Ethnopharmacol. 2023. 303, 115938. https://doi.org/10.1016/j.jep.2022.115938.

35. Abu Bakar, A.R.; Manaharan, T.; Merican, A.F.; Mohamad, S.B. Experimental and computational approaches to reveal the potential of *Ficus deltoidea* leaves extract as α-amylase inhibitor. Nat. Prod. Res. 2018, 32(4), 473-476. https://doi.org/10.1080/14786419.2017.1312393

36. El-Hawary, S.S.; Mubarek, M.M.; Lotfy, R.A.; Hassan, A.R.; Sobeh, M.; Okba, M.M. Validation of Antidiabetic Potential of *Gymnocarpos decandrus* Forssk. Nat. Prod. Res. 2021, 35(24), 5954-5959. https://doi.org/10.1080/14786419.2020.1805608

37. El-Hawary, S.S.; Mubarek, M.M. Lotfy, R.A.; Sleem, A.A.; Okba, M.M. In vivo antidiabetic potential of standardized *Gymnocarpos decandrus* Forssk. extract. J. Diabet. Metab. Disord. 2021, 20(2), 1129-1135. https://doi.org/10.1007/s40200-021-00829-9.

38. Bashir, K.; Naz, S.; Rasheed, H.M.; Farooq, U.; Shah, A.J.; McCauley, P. Crews, E.P.; Khan, T. Tandem high resolution mass spectrometry based phytochemical composition of *Sauromatum guttatum* tubers and its enzyme inhibitory potential with molecular docking. J. Chromatogr. A. 2022, 1672, 463055. https://doi.org/10.1016/j.chroma.2022.463055

39. Saeting, O.; Chandarajoti, K.; Phongphisutthinan, A.; Hongsprabhas, P.; Sae-Tan, S.; Water extract of Mungbean *(Vigna radiata L.)* inhibits protein tyrosine phosphatase-*1B* in insulin-resistant HepG2 cells. Molecules, 2021. 26(5). https://doi.org/10.3390/molecules26051452.

40. Ravichandran, G.; Lakshmanan, D.K.; Murugesan, S.; Elangovan, A.; Rajasekaran, N.S.; Thilagar, S. Attenuation of protein glycation by functional polyphenolics of dragon fruit *(Hylocereus polyrhizus)*; an in vitro and in silico evaluation. Food Res. Int. 2021, 140, 110081. https://doi.org/10.1016/j.foodres.2020.110081

41. Kan, R.; Ren, P.; Wu, A.; Tang, Q.; Kong, B.; Xue, C. Identification and molecular docking study of sugarcane leaf-derived compounds as potent dipeptidyl peptidase IV, α-glucosidase, and α-amylase inhibitors. J. Sci. Food. Agric. 2023. 103(11), 5388-5400. https://doi.org/10.1002/jsfa.12613.

42. Kagawa, M.; Fujimoto, Z.; Momma, M.; Takase, K.; Mizuno, H. Crystal structure of *Bacillus subtilis* alpha-amylase in complex with acarbose. J. Bacteriol. 2003, 185(23), 6981-4. 10.1128/jb.185.23.6981-6984.2003. https://doi.org/10.2210/pdb6toz/pdb

43. Halim, S.A.; Jabeen, S.; Khan, A.; Al-Harrasi, A. Rational design of novel inhibitors of α-glucosidase: An application of quantitative structure activity relationship and structure-based virtual screening. Pharmaceuticals, 2021, 14(5). https://doi.org/10.3390/ph14050482.

44. Syihabudin, V.; lohita sari, B.; Utami, N.F.; Apriliani, N.A. Inhibitory activity of a-glucosidase of bark of *Ceiba pentandra* Linn. Indones. J. Pharm. 2018, 29, 206-213. https://doi.org/10.14499/indonesianjpharm29iss4pp206.

45. Charoensiddhi, S.; Chanput, W.P.; Sae-Tan, S. Gut microbiota modulation, anti-diabetic and anti-inflammatory properties of polyphenol extract from mung bean seed coat *(Vigna radiata* L.*).* Nutrients. 2022, 14(11). https://doi.org/10.3390/nu14112275.

46. Ganesan, K.; Ramkumar, K.M.; Xu, B. Vitexin restores pancreatic β-cell function and insulin signaling through Nrf2 and NF-κB signaling pathways. Eur. J. Pharmacol. 2020, 888, 173606. https://doi.org/10.1016/j.ejphar.2020.173606

47. Casanova, L.M.; Gu, W.; Costa, S.S.; Jeppesen, P.B. Phenolic substances from Ocimum species enhance glucose-stimulated insulin secretion and modulate the expression of key insulin regulatory genes in mice pancreatic islets. J. Nat. Prod. 2017. 80(12), 3267-3275. https://doi.org/10.1021/acs.jnatprod.7b00699.

48. Almahmoud, S.; Wang, X.; Vennerstrom, J.L.; Zhong, H.A.; Conformational studies of glucose transporter 1 (GLUT1) as an anticancer drug target. Molecules. 2019, 24(11). 10.3390/molecules24112159. https://doi.org/10.3390/molecules24112159

49. Park, M.S.; Molecular dynamics simulations of the human glucose transporter GLUT1. PLoS One. 2015, 10(4), e0125361. https://doi.org/10.1371/journal.pone.0125361.

50. Pantaleão, J.A.F.; Carvalho-Batista, A.; Teodoro, S.S.A.; Costa, R.C. The influence of environmental variables in the reproductive performance of *Macrobrachium amazonicum* (Heller, 1862) (Caridea: Palaemonidae) females in a continental population. An. Acad. Bras. Cienc. 2018, 90(2), 1445-1458. https://doi.org/10.1590/0001-3765201820170275.

51. Kirby, M.; Yu, D.M.; O'Connor, S.; Gorrell, M.D. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clinz. Sci. (Lond), 2009, 118(1), 31-41. https://doi.org/10.1042/cs20090047.

52. Choi, J.S; Islam, M.N.; Ali, M.Y.; Kim, E.J.; Kim, Y.M.; Jung, H.A. Effects of C-glycosylation on anti-diabetic, anti-Alzheimer's disease and anti-inflammatory potential of apigenin. Food. Chem. Toxicol. 2014. 64, 27-33. https://doi.org/10.1016/j.fct.2013.11.020.

53. Balli, D.; Bellumori, M.; Paoli, P.; Pieraccini, G.; Di Paola, M.; De Filippo, M.; Di Gioia, D.; Mulinacci, N.; Innocenti, M. Study on a fermented whole wheat: phenolic content, activity on PTP1B enzyme and in vitro prebiotic properties. Molecules. 2019, 24(6). https://doi.org/10.3390/molecules24061120

54. Rampadarath, A.; Balogun, F.O.; Pillay, C.; Sabiu, S.; Identification of flavonoid C-glycosides as promising antidiabetics targeting protein tyrosine phosphatase

1B. J. Diabetes. Res. 2022, 6233217. https://doi.org/10.1155/2022/6233217

55. Jin, T.; Yu, H.; Huang, X.F.; Selective binding modes and allosteric inhibitory effects of lupane triterpenes on protein tyrosine phosphatase 1B. Sci. Rep. 2016, 6, 20766. https://doi.org/10.1038/srep20766.

56. Jeong, K.M.; Yang, M.; Jin, Y.; Kim, E.M.; Ko, J.; Lee, J. Identification of major flavone C-glycosides and their optimized extraction from *Cymbidium kanran* using deep eutectic solvents. Molecules. 2017, 22(11). https://doi.org/10.3390/molecules22112006

57. Boudjelal, A.; Siracusa, L.; Henchiri, C.; Sarri, M.; Abderrahim, B.; Baali Ruberto, F. Antidiabetic effects of aqueous infusions of *Artemisia herba-alba* and *Ajuga iva* in alloxan-induced diabetic rats. Planta Med. 2015, 81(9), 696-704. https://doi.org/10.1055/s-0035-1546006

58. Dib, I.; Tits, M.; Angenot, L. Wauters, J.N. Assaidi, A. Mekhfi, H. Aziz, M. Bnouham, M. Legssyer, A. Frederich, M. Ziyyat, A. Antihypertensive and vasorelaxant effects of aqueous extract of A*rtemisia campestris* L. from Eastern Morocco. J. Ethnopharmacol. 2017, 206, 224-235. https://doi.org/10.1016/ j.jep.2017.05.036

59. Akoonjee, A.; Rampadarath, A.; Aruwa, C.E.; Ajiboye, T.A.; Ajao, A.A.; Sabiu, S. Network pharmacology- and molecular dynamics simulation-based bioprospection of *Aspalathus linearis* for type-2 diabetes care. Metabolites. 2022, 12(11), 1-013. https://doi.org/10.3390/metabo12111013

60. Mohammed, H.S.; Abdel-Aziz, M.M.; Abu-Baker, M.S.; Saad, A.M.; Mohamed, M.A.; Ghareeb, M.A. Antibacterial and potential antidiabetic activities of flavone C-glycosides isolated from *Beta vulgaris* subspecies Cicla L. var. Flavescens (Amaranthaceae) cultivated in Egypt. Curr. Pharm. Biotechnol. 2019, 20(7), 595-604. https://doi.org/10.2174/1389201020666190613161212

61. Xu, G.K.; Qin, X.Y.; Wang, G.K.; Xie, G.Y.; Li, X.S.; Sun, C.Y.; Liu, B.L.; Qin, M.J. Antihyperglycemic, antihyperlipidemic and antioxidant effects of standard ethanol extract of *Bombax ceiba* leaves in high-fat-diet- and streptozotocin-induced Type 2 diabetic rats. Chin. J. Nat. Med. 2017, 15(3), 168-177. https://doi.org/10.1016/s1875-5364(17)30033-x

62. Murugesu, S.; Ibrahim, Z.; Ahmed, Q.U.; Nik Yusoff, N.I.; Uzir, B.F.; Perumal, V.; Abas, F.; Saari, K.; El-Seedi, H.; Khatib, A. Characterization of α-glucosidase inhibitors from *Clinacanthus nutans* Lindau leaves by gas chromatography-mass spectrometry-based metabolomics and molecular docking simulation. Molecules. 2018, 23(9). https://doi.org/ 10.3390/molecules23092402

63. Ong, W.Y.; Herr, D.R.; Sun, G.Y.; Lin, T.N.; Anti-inflammatory effects of phytochemical components of *Clinacanthus nutans*. Molecules. 2022, 27(11). https://doi.org/10.3390/molecules27113607

64. de Beer, D.; Schulze, A.E.; Joubert, E.; de Villiers, A.; Malherbe, C.J.; Stander, M.A. Food ingredient extracts of *Cyclopia subternata* (Honeybush): variation in phenolic composition and antioxidant capacity. Molecules. 2012, 17(12), 14602-24. https://doi.org/10.3390/molecules171214602

65. Ku, S.K.; Bae, J.S. Vicenin-2 and scolymoside inhibit high-glucose-induced vascular inflammation in vitro and in vivo. Can. J. Physiol. Pharmacol. 2016, 94(3), 287-95. https://doi.org/10.1139/cjpp-2015-0215

66. Ho, K.L; Yong, P.H.; Wang, C.W.; Kuppusamy, U.R.; Ngo, C.T.; Massawe, F.; Ng, Z.X. *Peperomia pellucida* (L.) Kunth and eye diseases: A review on phytochemistry, pharmacology and toxicology. J. Integr. Med. 2022, 20(4), 292-304. https://doi.org/10.1016/j.joim.2022.02.002

67. Abdul-Wahab, I.R.; Guilhon, C.C.; Fernandes, P.D.; Boylan, F. Anti-nociceptive activity of Pereskia bleo Kunth. (Cactaceae) leaves extracts. J. Ethnopharmacol. 2012, 144(3), 741-6. https://doi.org/10.1016/ j.jep.2012.10.029.

68. Sharifi-Rad, J.; Kobarfard, F.; Ata, A.; Ayatollahi, S.A.; Khosravi-Dehaghi, N.; Jugran, A.K.; Tomas, M.; Capanoglu, E.; Matthews, K.R.; Popović-Djordjević, J.; Kostić, A.; Kamiloglu, S.; Sharopov, F.; Choudhary, M.I.; Martins, N. Prosopis plant chemical composition and pharmacological attributes: targeting clinical studies from preclinical evidence. Biomolecules. 2019, 9(12). https://doi.org/10.3390/biom9120777.

69. Gong, J.; Fang, K.; Dong, H.; Wang, D.; Hu, M.; Lu, F. Effect of fenugreek on hyperglycaemia and hyperlipidemia in diabetes and prediabetes: A meta-analysis. J. Ethnopharmacol. 2016, 194, 260-268. https://doi.org/10.1016/j.jep.2016.08.003.

70. Idris, S.; Mishra, A.; Khushtar, M. Recent therapeutic interventions of fenugreek seed: A mechanistic approach. Drug Res. (Stuttg). 2021. 71(4), 180-192. https://doi.org/10.1055/a-1320-0479.

71. Aumeeruddy, M.Z. and M.F. Mahomoodally, Ethnomedicinal plants for the management of diabetes worldwide: A systematic review. Curr. Med. Chem. 2021, 28(23), 4670-4693. https://doi.org/10.2174/0929867328666210121123037.

72. Kang, H.; Ku, S.K.; Jung, B.; Bae, J.S.; Anti-inflammatory effects of vicenin-2 and scolymoside in vitro and in vivo. Inflamm. Res. 2015, 64(12), 1005-21. https://doi.org/10.1007/s00011-015-0886-x.